Antibody-drug conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines, or cytotoxins via chemical linkers with labile bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue.
The report titled “Global Antibody Drug Conjugate Market: Growth, Future Prospects, and Competitive Analysis, 2016–2024” offers strategic insights into the overall Antibody Drug Conjugate market, along with the market size and estimates for the duration of 2016 to 2024. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.
In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global antibody drug conjugate market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:
Geographically, the global antibody drug conjugate market is studied for the following regional markets:
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2024. Market growth rates for the forecast period 2016–2024 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global antibody drug conjugate market. Pipeline analysis of the drugs currently in the clinical trial stage is also included in the report. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of the global antibody drug conjugate market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global antibody drug conjugate market. In-depth competitive environment analysis and historical 2014 market size data are also provided in the report.
Thus, the research study provides a holistic view of the global antibody drug conjugate market, offering market size and estimates for the period from 2016 to 2024, keeping in mind the above-mentioned factors.
Based on the type of drug, the antibody-drug conjugate market is segmented into:
Antibody-drug conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. By attaching biologically active chemotherapeutic drugs, radioactive isotopes, cytokines, or cytotoxins via chemical linkers with labile bonds to a monoclonal antibody directed to antigens differentially overexpressed in tumor cells, ADCs significantly improve sensitive discrimination between healthy and diseased tissue. Currently, marketed drugs suffer from various stipulations, like low potency, a lack of specificity, and adverse effects. This has forced pharmaceutical and research companies to develop therapeutics that can overcome these barriers. Commercializing antibody-drug conjugates has overcome these scenarios and improved medical conditions. The two currently marketed antibody-drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche). Additionally, there are more than 50 molecules in the pre-clinical stage. Out of these, approximately 25% are in Phase II or Phase III of development, leading to a rapidly expanding pre-clinical pipeline. With over 190 active clinical trials, antibody-drug conjugates are gaining popularity around the world because they provide superior pharmacological efficiency while minimizing side effects.
For the purpose of this study, the global market for antibody-drug conjugates is categorized as follows:
- North America
- Asia Pacific
- Rest of the World
The geographical segmentation of the global antibody drug conjugate market comprises North America, Europe, Asia-Pacific, and the Rest of the World. In the base year of 2015, North America accounted for the largest market in the antibody-drug conjugate market due to the presence of major pharmaceutical companies working on the development of antibody-drug conjugate drugs. Moreover, one of the prime reasons for North America’s dominance in the antibody drug conjugates market is the fast-track approval and commercialization of ADCs in the region as compared to other geographical regions. Europe held the second-largest market for antibody-drug conjugates. Kadcyla, one of the two drugs that are marketed currently, is manufactured by the Europe-based pharmaceutical giant Roche. Additionally, Europe was the second region after the United States, where the commercialization of ADCs was approved on a fast-track basis. There are currently more than 190 clinical trials being carried out in Europe and North America. Asia Pacific is anticipated to be the fastest-growing segment in the antibody-drug conjugate market due to the approval of ADCs in Japan and China. Kadcyla was approved and launched in the Indian market as a premium-priced drug in 2015. Fast-track approvals of breakthrough drugs in Asia-Pacific would further drive the antibody-drug conjugate market during the forecast period.